Iron Overload Disorders Therapeutics
1. Exjade patent expiration
Treatment: Method of treating chronic iron overload
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6596750 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun, 2017
(8 years ago) | |
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 02, 2012 |
| New Indication(I-665) | Jan 23, 2016 |
| Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
| M(M-239) | Dec 12, 2021 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 02 November, 2005
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of EXJADE before it's drug patent expiration?
More Information on Dosage
EXJADE family patents
2. Ferriprox patent expiration
Treatment: Method of treating transfusional iron overload
FERRIPROX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7049328 | CHIESI | Use for deferiprone |
Jun, 2021
(4 years ago) | |
| US11723874 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(3 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-418) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-419) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
Drugs and Companies using DEFERIPRONE ingredient
NCE-1 date: 15 October, 2015
Market Authorisation Date: 25 July, 2019
Dosage: TABLET; SOLUTION
How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage
FERRIPROX family patents